Net Loss Per Share Attributable to Common Stockholders (Tables)

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Preferred stock (if converted)		-		7,039,155		-		7,039,155
Options to purchase common stock		546,068		410,292		489,059		417,569
Contingently issuable common stock upon exchange of    Vaccinex Products, LP units		1,199,021		1,202,566		1,200,794		1,202,566
Contingently issuable common stock upon exchange of    VX3 units		1,318,797		1,176,288		1,318,797		994,558